The comparison of effects of two drugs in neutropenic patients

The comparison of effects of Filgrastim and Peg-Filgrastim in neutropenic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201205279875N1

Enrollment

Registered

2014-03-01

Start date

2012-09-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neutropenia. Neutropenia

Interventions

Intervention 1: Filgrastim, subcutaneously, 5-10 µg/kg, daily, to 7 days. Intervention 2: Pegfilgrastim, Ampule subcutaneously,100 µg/kg as a single dose.

Treatment - Drugs

Filgrastim, subcutaneously, 5-10 µg/kg, daily, to 7 days

Pegfilgrastim, Ampule subcutaneously,100 µg/kg as a single dose

Eligibility

Sex/Gender

All

Age

1 Years to 16 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Patients with leukemia or solid tumor; Neutropenia due to infection or chemotherapy Exclusion criteria: Patients with drug reaction to investigation drugs; Failure to refer the patients to follow up.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Absolute Neutrophil Count. Timepoint: A week followig end of treatment. Method of measurement: Laboratory.	—

Secondary

Measure	Time frame
Drug side effect. Timepoint: 7 days after treatment. Method of measurement: Physical Examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeed Yousefian

Ali Asghar Hospital

yousefian??saeed@yahoo.com+98 21 2304 6411

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026